Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024

Euro Surveill. 2024 Feb;29(8). doi: 10.2807/1560-7917.ES.2024.29.8.2400089.ABSTRACTInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.PMID:38390651 | DOI:10.2807/1560-7917.ES.2024.29.8.2400089

Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Marine Maurel Jennifer Howard Esther Kissling Francisco Pozo Gloria P érez-Gimeno Silke Buda No émie Sève Adele McKenna Adam Meijer Ana Paula Rodrigues Iv án Martínez-Baz Ivan Mlinari ć Neus Latorre-Margalef Gerg ő Túri Mihaela Laz ăr Clara Mazag Source Type: research